EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 4.0

The first remote monitoring experience in South Korea: results of a remote-care study

YouMi Hwang iD, Hannah Bae iD

Europace · 2023

DOI: 10.1093/europace/euad150 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Europace, 2023. Verfasst von YouMi Hwang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, St. Vincent's Hospital, the Catholic University of Korea, 93, Jungbu-daero, Paldal-gu, Suwon-si 16247, Gyeonggi-do, Republi…. Hauptthemen laut MEDLINE: Pacemaker, Artificial, Defibrillators, Implantable. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cardiomessenger.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Remote monitoring (RM) of cardiac devices has been widely used for over 10 years, even before telehealth became well-known.1–6 Despite evidence of its efficacy and safety in other countries, the introduction of RM in Korea was delayed due to the conflict of opinions among experts from various fields and the unique National Health Insurance system. This study presents the outcome of the first RM experience in Korea. This prospective study in a single experienced centre evaluated the efficacy and safety of the cardiac device RM system in addition to patient experience surveys in RM naïve patients, in comparison to conventional in-office device follow-up. Patients with Biotronik cardiac implantable electronic devices (pacemakers, implantable cardioverter defibrillators, and cardiac resynchronization therapy with defibrillators) compatible with the home monitoring system were included in the study. All participating patients had been followed up conventionally in a clinic for more than six months and then assigned to RM after informed consent. Patients were followed up for 12 months for their RM use. Any unexpected visits or admission during the study period were classified as unplanned or planned (routine) visits and further subdivided into device-related, participants’ cardiovascular condition-related, and non-cardiovascular condition-related visits. Hospital waiting times and clinic consultation times were determined based on an automatic electronic medical record system. Medical costs were recorded throughout the study period to estimate the patient's payment and insurance payment required for each hospital visit. After obtaining informed consent, participants were requested to complete a questionnaire7 regarding their prior experience with conventional in-office visits before using RM. Per the study flow chart, after completing the pre-RM questionnaire, the patients (±caregivers) received a mobile CardioMessenger Smart device, which was immediately paired with their cardiac implantable electronic devices, along with instructions for CardioMessenger Smart and RM use. During the study, routine clinical follow-ups were scheduled at 6–12 months for patients with pacemakers and 3–6 months for patients with implantable cardioverter defibrillators. After 12 months of RM, patients were asked to complete two types of questionnaires. The primary endpoint was patient satisfaction after RM. The secondary endpoints included comparing time spent and qualitative evaluations, including medical costs between contact medical care and RM for cardiac implantable electronic device recipients and medical personnel. A total of 102 patients participated in the Remote-Care study after obtaining informed consent. During follow-up, five patients died before completing the study (all non-cardiovascular deaths), and the results were analysed excluding them (n = 97). The mean age of the studied patients was 71.2 ± 12.4 years. Among the examined patients, 79 had a pacemaker, 15 had implantable cardioverter defibrillators, and 3 had cardiac resynchronization therapy with a defibrillator. Since the number of pacemaker users was high in this study, the following results are more relevant to the RM of pacemakers. The average clinic visit number, hospital travel time, and waiting time decreased after RM. RM was associated with a 33% reduction in average medical expense per visit and an 8.3% reduction in average claimed fees reimbursed claimed costs to the healthcare provider. In general, more than 90% of the study participants were comfortable with RM, regardless of device type, and were willing to continue RM. However, at the end of the study, less than 4% of the patients refused RM persistence (Graphical abstract, bottom right figure) due to the anxiety of not being able to see the medical staff for a long time. There was a total of 1270 RM alerts to the primary investigator during the 12 months of the follow-up period. While 98.8% of these alerts were nonactionable, 1.2% was actionable. The caregiver/patient was contacted only if the alert was actionable. Alert burdens can be reduced by setting the individualized RM alert based on patients’ underlying cardiovascular diseases. This is the first prospective study with a survey of patients’ experience with RM in Korea. This study evaluated the safety and efficacy of RM and patient satisfaction after using RM in the absence of domestic evidence for RM-related policy or insurance guidance. Based on this study, there are undeniable time and socioeconomic benefits for patients with cardiac implantable electronic devices following the RM application. The investigators hope that this study will serve to represent the needs of patients and medical personnel, thereby promoting the widespread acceptance of the RM approach to cardiac implantable electronic devices in Korea. The study was approved by the Catholic University of Korea, St. Vincent’s Hospital Institutional Review Board (Suwon, South Korea; Institutional Review Board No. VC20DISF0160). The Remote-Care study was registered at ClinicalTrials.gov with the study ID NCT04557111. We sincerely thank Jin-gyu Choi and Jayhyeok Choi for their full support during the project and GangHyun Lee and JinAh Hwang for their help in RM. We want to thank Editage (www.editage.co.kr) for the English language editing. Biotronik supported this study by providing Cardiomessenger (Biotronik communicator for Biotronik CIED for remote monitoring service) instruction on Cardiomessenger and RM use. Due to the sensitive nature of the data, information created during and/or analysed during the current study is available from the corresponding author (Y.M.H., youmi0607@naver.com) on reasonable request to bona fide researchers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pacemaker, ArtificialDefibrillators, ImplantableHumansRepublic of KoreaRemote Sensing Technology

Stichwörter der Autor:innen

ArtificialCardiac resynchronization therapy devicesDefibrillatorsImplantablePacemakerRemote monitoring

Autor:innen und Institutionen

  • Department of Cardiology, St. Vincent's Hospital, the Catholic University of Korea, 93, Jungbu-daero, Paldal-gu, Suwon-si 16247, Gyeonggi-do, Republic of Korea.
  • Catholic Research Institute for Intractable Cardiovascular Disease (CRID), College of Medicine, the Catholic University of Korea, Seoul 06591, Republic of Korea.
  • Department of Economics, University of California San Diego, San Diego, CA, United States.

ORCID-Profile: YouMi Hwang, Hannah Bae

Förderung

  • Cardiomessenger

Zitieren

APA

Hwang, Y., & Bae, H. (2023). The first remote monitoring experience in South Korea: results of a remote-care study. Europace. https://doi.org/10.1093/europace/euad150

Vancouver

Hwang Y, Bae H. The first remote monitoring experience in South Korea: results of a remote-care study. Europace. 2023. doi:10.1093/europace/euad150

BibTeX
@article{Hwang2023,
  author = {Hwang, YouMi and Bae, Hannah},
  title = {The first remote monitoring experience in South Korea: results of a remote-care study},
  journal = {Europace},
  year = {2023},
  doi = {10.1093/europace/euad150}
}
Kostenlos starten →